Bacigalupo A
Department of Haematology, Ospedale San Martino, Genoa, Italy.
Eur J Cancer. 1994;30A Suppl 3:S26-9.
Recombinant human granulocyte colony stimulating factor (rHuG-CSF) has been used for several years in clinical haematology and it is now routinely employed to prevent or treat chemotherapy-induced neutropenia. rHuG-CSF is also administered after autologous or allogeneic bone marrow transplantation (BMT), since it can significantly shorten the duration of neutropenia. However, probably its main use at the moment is to facilitate the collection of peripheral blood stem cells (PBSC) from patients with lymphoma, myeloma and breast cancer. Within controlled trials, it is also used as an adjunct to immunosuppression for patients with aplastic anaemia. rHuG-CSF has a number of other potential uses such as increasing the numbers of progenitor cells for transplantation by in vivo and/or ex vivo amplification; treatment of non-neutropenic infections post transplant, and prophylaxis and treatment of cytomegalovirus infections. In the future, autologous stem cell transplants may be performed in the outpatient department thus expanding the use of PBSC transplantation to disease areas not previously considered suitable for such myelosuppressive treatment.
重组人粒细胞集落刺激因子（rHuG-CSF）已在临床血液学中使用多年，目前常用于预防或治疗化疗引起的中性粒细胞减少症。自体或异基因骨髓移植（BMT）后也会使用rHuG-CSF，因为它可以显著缩短中性粒细胞减少的持续时间。然而，目前其主要用途可能是促进从淋巴瘤、骨髓瘤和乳腺癌患者中采集外周血干细胞（PBSC）。在对照试验中，它还被用作再生障碍性贫血患者免疫抑制的辅助治疗。rHuG-CSF还有许多其他潜在用途，例如通过体内和/或体外扩增增加用于移植的祖细胞数量；治疗移植后的非中性粒细胞减少性感染，以及预防和治疗巨细胞病毒感染。未来，自体干细胞移植可能在门诊进行，从而将PBSC移植的应用扩展到以前认为不适合这种骨髓抑制治疗的疾病领域。
